Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Oct;12(4):535–542. doi: 10.1111/j.1365-2125.1981.tb01262.x

Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.

M B Youdim, A Hefez, B Oppenheim
PMCID: PMC1401896  PMID: 7295487

Abstract

1 Enhancement of platelet aggregation response (PAR) to 5-hydroxytryptamine (5-HT) in some schizophrenic patients receiving chlorpromazine (CPZ) may provide a biological index for the efficacy of this drug. 2 In a double-blind study 33 schizophrenic patients hospitalized following their first psychotic breakdown were followed up clinically with concurrent assessment of their PAR to 5-HT. The patients followed a standardized treatment schedule with (CPZ) as the sole antipsychotic medication. 3 Twelve patients (Group A) developed an enhanced biphasic 5-HT PAR, within 2-3 weeks and improved clinically by the sixth week. In most cases, the appearance of the enhanced biphasic PAR preceded clinical improvement. Twenty-one patients (Group B) did not have enhanced biphasic PAR to 5-HT by the sixteenth week of treatment. However, twelve subjects from this group showed clinical response to CPZ by the end of this period, while the remaining patients did not improve. 4 The enhanced PAR to 5-HT in Group A discriminated best between good and bad outcome cases when Feighner's research diagnostic criteria were used. We could not confirm the previous reports of platelet aggregation response to dopamine in pre- or post-chlorpromazine treatment.

Full text

PDF
535

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldacci M., Baldacci M., Bergel T. D., Born G. V., Hickman M. Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine. Br J Pharmacol. 1980 May;69(1):113–118. doi: 10.1111/j.1476-5381.1980.tb10889.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baumgartner H. R., Born G. V. Effects of 5-hydroxytryptamine on platelet aggregation. Nature. 1968 Apr 13;218(5137):137–141. doi: 10.1038/218137a0. [DOI] [PubMed] [Google Scholar]
  3. Born G. V., Michal F. 5-Hydroxytryptamine receptors of platelets. Ciba Found Symp. 1975;35:287–307. doi: 10.1002/9780470720172.ch14. [DOI] [PubMed] [Google Scholar]
  4. Boullin D. J., Grahame-Smith D. G., Grimes R. P., Woods H. F. Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol. 1975 Jan;53(1):121–125. doi: 10.1111/j.1476-5381.1975.tb07338.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boullin D. J., Know J. M., Peters J. R., Orr M. W., Gelder M. G., Grahame-Smith D. G. Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol. 1978 Dec;6(6):538–540. doi: 10.1111/j.1365-2125.1978.tb00881.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carpenter W. T., Jr, Strauss J. S., Bartko J. J. The diagnosis and understanding of schizophrenia. Part I. Use of signs and symptoms for the identification of schizophrenic patients. Schizophr Bull. 1974 Winter;(11):37–49. doi: 10.1093/schbul/1.11.37. [DOI] [PubMed] [Google Scholar]
  7. Feighner J. P., Robins E., Guze S. B., Woodruff R. A., Jr, Winokur G., Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972 Jan;26(1):57–63. doi: 10.1001/archpsyc.1972.01750190059011. [DOI] [PubMed] [Google Scholar]
  8. Freedman M. L., Karpatkin S. Requirement of iron for platelet protein synthesis. Biochem Biophys Res Commun. 1973 Sep 18;54(2):475–481. doi: 10.1016/0006-291x(73)91445-9. [DOI] [PubMed] [Google Scholar]
  9. Graf M., Pletscher A. Shape change of blood platelets--a model for cerebral 5-hydroxytryptamine receptors? Br J Pharmacol. 1979 Apr;65(4):601–608. doi: 10.1111/j.1476-5381.1979.tb07870.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Oppenheim B., Hefez A., Youdim M. B. Serotonin receptor site in human platelets from control and chlorpromazine treated subjects. Prog Biochem Pharmacol. 1980;16:119–132. [PubMed] [Google Scholar]
  11. Preiser M., Jeffrey W. Schizophrenic patients and Schneiderian first-rank symptoms. Am J Psychiatry. 1979 Mar;136(3):323–326. doi: 10.1176/ajp.136.3.323. [DOI] [PubMed] [Google Scholar]
  12. Seeman P. Anti-schizophrenic drugs--membrane receptor sites of action. Biochem Pharmacol. 1977 Oct 1;26(19):1741–1748. doi: 10.1016/0006-2952(77)90340-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES